Cipla Limited delivered its highest-ever first-quarter revenue, reporting consolidated sales of ₹7,119 crore for Q1FY27, marking a 2% year-on-year increase. The pharmaceutical major posted a profit after tax (PAT) of ₹789 crore, representing 11% of sales, while maintaining a robust balance sheet with net cash equivalent to ₹9,494 crore as of June 30, 2026. This performance underscores the resilience of Cipla’s diversified portfolio, particularly in its One India business which achieved record quarterly revenue with 12% growth.

The revenue growth was primarily fueled by the branded prescription business in India, which expanded by 15.4% according to IQVIA data. Key therapeutic areas such as anti-diabetes (43% growth), cardiac (20%), and respiratory (15%) contributed significantly to this momentum. Globally, North America generated $162 million in revenue, bolstered by the successful launch of generic Ventolin and continued strength in the albuterol MDI market where Cipla holds a 21% share. However, South Africa faced headwinds from tender losses, though its private market grew 6.5%, outpacing the overall market.

Financial Highlights

Effective April 1, 2026, Cipla revised its financial presentation to treat certain marketing and proportional expenditures as a reduction from revenue rather than operating expenses. This accounting change impacted the reported growth rates; management indicated that adjusted growth would be approximately 4%. The gross margin of 62.5% reflected pressures from product mix shifts, war-related costs estimated at 1-2% of revenue, and inventory write-offs.

Strategic Outlook and Pipeline

Management reaffirmed its target to achieve an exit run rate of $1 billion for the US business by FY27. This trajectory relies on four significant upcoming launches: three respiratory assets, including generic Advair, and one large peptide opportunity. Two of the respiratory filings originate from US manufacturing facilities, while the third is from Goa. The recent US FDA inspection of the Verna, Goa facility was classified as Voluntary Action Indicated (VAI), and a routine inspection at the Invagen facility in New York resulted in one Form 483 observation, which the company is addressing within the stipulated timeline.

In India, the chronic therapy mix strengthened to 60.4% year-on-year. The company added two new brands to its ₹100-plus crore club, bringing the total to 33. New launches such as Duolin Synchrobreathe in respiratory and UPADACIP in immunology are expected to deepen market penetration. For FY27, Cipla maintains its EBITDA margin guidance of 18.5% to 20%, contingent on the successful execution of these new product launches and cost optimization initiatives.

Cipla reported a record consolidated revenue of INR 7,119 crore for the first quarter of FY27 (Q1FY27), driven by double-digit growth in its One India business and new product launches in North America. Despite the top-line milestone, profitability metrics contracted significantly year-on-year, with EBITDA falling to INR 1,192 crore (margin 16.7%) from INR 1,778 crore (25.6%) in Q1FY26, and PAT declining to INR 789 crore (11.1%) from INR 1,298 crore (18.7%). The company maintained its full-year FY27 EBITDA margin guidance of 18.5% to 20%, citing upcoming pipeline approvals.

Financial Performance Snapshot

The revenue growth was broad-based, with One India contributing the largest share at 48% of total revenue. The region posted its highest-ever quarterly revenue of INR 3,452 crore, representing a 12% year-on-year increase. North America contributed 22% ($162 million), while Emerging Markets & Europe and One Africa each accounted for 14%.

The decline in margins was primarily attributed to higher material costs (INR 2,667 crore vs INR 2,171 crore in Q1FY26) and increased employee benefits expenses (INR 1,497 crore vs INR 1,312 crore). Other operating income also dropped sharply to INR 42 crore from INR 120 crore in the prior year.

Regional Business Updates

One India: Chronic Therapies Lead Growth

One India’s branded prescription segment maintained its #2 rank in overall chronic therapies, with the chronic mix improving to 60.4%. Key therapeutic areas saw double-digit growth: Anti-diabetic (+26%), Cardiac (+14%), Respiratory (+13%), Dermatology (+11%), and Urology (+10%). The company launched several new products, including Yurpeak, Duolin Syncrobreathe, Doloneuron, and Nasowash. Its flagship respiratory brand, Foracort, crossed the INR 1,000 crore mark. In consumer health, anchor brands Nicotex, Omnigel, and Cipladine retained market leadership.

North America: gVentolin Launch

Cipla launched its first AB-rated generic Ventolin (gVentolin) in the US market during the quarter, with initial shipments executed. The company plans a supply ramp-up over coming quarters. This launch is critical to achieving its target of a $1 billion run rate for the North America business by FY27. Additionally, gProventil ranked No. 1 in the overall US Albuterol MDI market with a 21% share. Other recent launches include Nintedanib, Dapagliflozin, and Liraglutide.

One Africa and Emerging Markets

In South Africa, the private label business grew faster than the market (1.2x), with prescription revenue growing 9.8% against a market growth of 6.9%. Cipla held an 8.8% market share in SA Prescription. Emerging Markets & Europe grew 5% YoY to $106 million.

Pipeline and ESG Progress

As of June 30, 2026, Cipla’s US pipeline included 103 approved ANDAs/NDAs, 19 tentatively approved, and 38 under approval. The total portfolio stands at 278 ANDAs/NDAs across all statuses. On the sustainability front, Cipla achieved 57% renewable electricity share for India manufacturing and maintained zero fatalities in operations. Its South Africa manufacturing unit achieved Net Zero Waste Certification.

What the Numbers Show

While top-line growth confirms demand resilience, the sharp contraction in EBITDA and PAT margins highlights cost inflation pressures and a drop in other income. The divergence between revenue growth (+2.3%) and profit decline (-39% PAT) suggests that operational efficiencies have not yet offset rising input costs. However, management’s retention of the 18.5–20% FY27 EBITDA margin guidance implies confidence that new launches, particularly gVentolin in the US, will drive margin recovery in subsequent quarters.